CN103181898B - 一种奥沙利铂脂质体及其应用 - Google Patents
一种奥沙利铂脂质体及其应用 Download PDFInfo
- Publication number
- CN103181898B CN103181898B CN201210487269.8A CN201210487269A CN103181898B CN 103181898 B CN103181898 B CN 103181898B CN 201210487269 A CN201210487269 A CN 201210487269A CN 103181898 B CN103181898 B CN 103181898B
- Authority
- CN
- China
- Prior art keywords
- oxaliplatin
- phospholipid
- liposome
- aqueous solution
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title claims abstract description 52
- 229960001756 oxaliplatin Drugs 0.000 title claims abstract description 52
- 239000002502 liposome Substances 0.000 title claims abstract description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 20
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- 229960000502 poloxamer Drugs 0.000 claims abstract description 11
- 229920001983 poloxamer Polymers 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 229940067631 phospholipid Drugs 0.000 claims description 10
- 229940107161 cholesterol Drugs 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000002245 particle Substances 0.000 abstract description 5
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 239000011973 solid acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210487269.8A CN103181898B (zh) | 2012-11-23 | 2012-11-23 | 一种奥沙利铂脂质体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210487269.8A CN103181898B (zh) | 2012-11-23 | 2012-11-23 | 一种奥沙利铂脂质体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103181898A CN103181898A (zh) | 2013-07-03 |
CN103181898B true CN103181898B (zh) | 2016-03-09 |
Family
ID=48673515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210487269.8A Active CN103181898B (zh) | 2012-11-23 | 2012-11-23 | 一种奥沙利铂脂质体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103181898B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105267147B (zh) * | 2014-07-08 | 2019-04-02 | 广州瑞济生物技术有限公司 | 一种注射用奥沙利铂前体脂质体的制备方法 |
CN106955271A (zh) * | 2016-01-08 | 2017-07-18 | 佛山英特医药科技有限公司 | 奥沙利铂聚集体及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628638A (zh) * | 2003-12-17 | 2005-06-22 | 梅比欧法姆股份有限公司 | 含有奥沙利铂的脂质体制剂 |
CN101103972A (zh) * | 2007-07-13 | 2008-01-16 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂及其制备方法、应用 |
CN101391098A (zh) * | 2008-11-11 | 2009-03-25 | 中国药科大学 | 一种蜂毒素脂质体制剂及其制备方法 |
CN101579312A (zh) * | 2008-05-16 | 2009-11-18 | 中国科学院上海药物研究所 | 替尼泊甙脂质体及其制备方法 |
CN101897668A (zh) * | 2009-05-27 | 2010-12-01 | 上海医药工业研究院 | 一种奥沙利铂脂质体及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05008489A (es) * | 2003-02-11 | 2005-10-18 | Neopharm Inc | Procedimiento de fabricacion para preparaciones liposomicas. |
DK2508170T3 (en) * | 2009-12-03 | 2015-09-21 | Jiangsu Hengrui Medicine Co | LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE |
-
2012
- 2012-11-23 CN CN201210487269.8A patent/CN103181898B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628638A (zh) * | 2003-12-17 | 2005-06-22 | 梅比欧法姆股份有限公司 | 含有奥沙利铂的脂质体制剂 |
CN101103972A (zh) * | 2007-07-13 | 2008-01-16 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂及其制备方法、应用 |
CN101579312A (zh) * | 2008-05-16 | 2009-11-18 | 中国科学院上海药物研究所 | 替尼泊甙脂质体及其制备方法 |
CN101391098A (zh) * | 2008-11-11 | 2009-03-25 | 中国药科大学 | 一种蜂毒素脂质体制剂及其制备方法 |
CN101897668A (zh) * | 2009-05-27 | 2010-12-01 | 上海医药工业研究院 | 一种奥沙利铂脂质体及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation;J. L. TIAN et al.;《ORIGINAL ARTICLES》;20111231;第66卷;第362–367页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103181898A (zh) | 2013-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102218036A (zh) | 奥美拉唑钠脂质体组合药物配方及制备方法和用途 | |
CN102617843A (zh) | 一种生物医用氨基酸-聚醚-聚酯三嵌段共聚物的制备 | |
CN101897668B (zh) | 一种奥沙利铂脂质体及其制备方法和用途 | |
US20120225117A1 (en) | Process for production of w/o/w emulsion, process for production of liposome employing the process, and porous membrane for use in the processes | |
KR101480055B1 (ko) | 음이온성 약물 전달체의 제조 방법 | |
CN114213295B (zh) | 一种阳离子化合物、制备方法及其复合物和用途 | |
CN103181898B (zh) | 一种奥沙利铂脂质体及其应用 | |
CN111420068B (zh) | 聚乙二醇-树枝状聚赖氨酸/酸酐-顺铂复合物及其制备方法和应用 | |
CN113975234A (zh) | 一种羟基-α-山椒素纳米脂质体及其制备方法 | |
WO2012137834A1 (ja) | 小胞体の製造方法 | |
EP3235561B1 (en) | Liposome production method and liposome production device | |
CN104667286A (zh) | 一种尺寸单分散性聚合物纳米囊泡及其制备方法和应用 | |
CN103610639B (zh) | 含缓冲盐的聚合物胶束载药组合物及其制备方法 | |
CN103520112A (zh) | 小粒径纳米颗粒的制备方法及纳米颗粒药物载体 | |
CN103169659A (zh) | 一种奥沙利铂长循环脂质体及其应用 | |
CN107412162B (zh) | 一种提高喜树碱在嵌段共聚物胶束中载药量的方法 | |
CN102274185A (zh) | 抗肿瘤pH敏感脂质体、其冻干粉针制剂及它们的制备方法 | |
CN102225053B (zh) | 长春新碱纳米靶向缓释长循环脂质体及制备方法 | |
CN114748425A (zh) | 一种人参皂苷Rb1脂质体及其制备方法 | |
CN107753433B (zh) | 一种纳米蛹虫草肽脂质体及其制备方法和一种口服液制剂 | |
CN108096218A (zh) | 一种载柴胡皂甙a的纳米颗粒及其制备方法 | |
CN107281163B (zh) | 羧基化合物在促进载药纳米粒微球口服吸收方面的应用 | |
CN115282119B (zh) | 一种高载药量脂质体及其制备方法 | |
CN113698589B (zh) | 一种维生素e琥珀酸酯磷脂化合物及其应用 | |
CN116869937A (zh) | 一种抗癌天然产物藤黄酸的纳米制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240403 Address after: Buildings 1-4, North Building 3, Medical Device Technology Industrial Park, No.1 Yunhai Road, Lihai Street, Yuecheng District, Shaoxing City, Zhejiang Province, 312000 Patentee after: Zhejiang Zhida Pharmaceutical Co.,Ltd. Country or region after: China Address before: Hangzhou City, Zhejiang province 310036 Xiasha Higher Education Park forest Street No. 16 Patentee before: Hangzhou Normal University Country or region before: China |
|
TR01 | Transfer of patent right |